Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 18/20 | 0.55 |
| ▸ | HSD17B2 | P37059 | 17/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.53 |
| ▸ | RET | P07949 | 1/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5179594 | 0.82 | ESR1 (0.50) | HSD17B1HSD17B2CYP3A4CYP2C9RET | |
| SCHEMBL48894 | 0.80 | DYRK1A (0.55) | DYRK1A | |
| SCHEMBL24271909 | 0.79 | KDR (0.54) | DYRK1A | |
| Ammonia Solution, Strong SCHEMBL28177501 | 0.78 | DYRK1A (0.53) | DYRK1A | |
| SCHEMBL29441698 | 0.78 | MAP4K4 (0.53) | CYP3A4DYRK1A | |
| SCHEMBL16159089 | 0.78 | DYRK1A (0.50) | HSD17B1HSD17B2CYP3A4CYP2C9DYRK1A | |
| SCHEMBL30667797 | 0.78 | DYRK1A (0.50) | DYRK1A | |
| SCHEMBL32671911 | 0.78 | CD38 (0.53) | HSD17B1HSD17B2CYP3A4DYRK1A | |
| SCHEMBL17063922 | 0.78 | CD38 (0.53) | RETDYRK1A | |
| SCHEMBL14320363 | 0.78 | MAP4K4 (0.53) | CYP3A4DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111344284-B | Compounds useful as inhibitors of isoprene cysteine carboxymethyltransferase | 新加坡科技研究局 | 2024-03-12 | — | — | CN | disclosed |
| US-11834430-B2 | Compounds useful as inhibitors of isoprenylcysteine carboxyl methyltransferase | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-12-05 | — | — | US | disclosed |
| US-11834430-B2 | Compounds useful as inhibitors of isoprenylcysteine carboxyl methyltransferase | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-12-05 | — | — | US | disclosed |
| US-11834430-B2 | Compounds useful as inhibitors of isoprenylcysteine carboxyl methyltransferase | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-12-05 | — | — | US | disclosed |
| US-20210130317-A1 | Compounds Useful as Inhibitors of Isoprenylcysteine Carboxyl Methyltransferase | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2021-05-06 | — | — | US | disclosed |
| US-20210130317-A1 | Compounds Useful as Inhibitors of Isoprenylcysteine Carboxyl Methyltransferase | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2021-05-06 | — | — | US | disclosed |
| EP-3773552-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC Therapeutics, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3681878-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ISOPRENYLCYSTEINE CARBOXYL METHYLTRANSFERASE | Agency for Science, Technology and Research (SG) | 2020-07-22 | — | — | EP | disclosed |
| CN-111344284-A | Compounds useful as inhibitors of isoprene cysteine carboxymethyltransferase | 新加坡科技研究局 | 2020-06-26 | — | — | CN | disclosed |
| WO-2019191229-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. (US) | 2019-10-03 | — | — | WO | disclosed |
| US-20120071462-A1 | Dihydrobenzoxathiazepine compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2012-03-22 | — | — | US | disclosed |
| WO-2012035216-A1 | DIHYDROBENZOXATHIAZEPINE DERIVATIVES, PREPARATION THEREOF, PHARMACEUTICAL COMPOSITIONS AND USE AS AMPA RECEPTOR MODULATORS | LES LABORATOIRES SERVIER (FR) | 2012-03-22 | — | — | WO | disclosed |
| EP-2431360-A1 | Derivatives of dihydrobenzoxathiazepine, method of preparing same and pharmaceutical compositions containing them as well as their uses as modulators of AMPA receptors | Les Laboratoires Servier (FR) | 2012-03-21 | — | — | EP | disclosed |
| US-20100216788-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-26 | — | — | US | disclosed |
| CN-101370812-A | Fused heterocyclic compound | TAKEDA PHARMACEUTICAL (JP) | 2009-02-18 | — | — | CN | disclosed |
| EP-1957495-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007064045-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-07 | — | — | WO | disclosed |
| US-5439932-A | Anticholesterol agents | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1995-08-08 | — | — | US | disclosed |
| US-5306728-A | Substituted amine derivatives having antihyperlipemia activity | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1994-04-26 | — | — | US | disclosed |
| EP-0448078-A2 | Substituted amine derivatives having anti-hyperlipemia activity | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1991-09-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130317-A1 | Compounds Useful as Inhibitors of Isoprenylcysteine Carboxyl Methyltransferase | ICMT, INMT, BHMT | HSD17B1 425/4885HSD17B2 559/4885CYP3A4 859/4885 |
| US-20120071462-A1 | Dihydrobenzoxathiazepine compounds, a process for their preparation and pharmaceutical compositions containing them | GABRA1, GRM1, GABRA5 | HSD17B1 340/4885HSD17B2 387/4885CYP3A4 134/4885 |
| US-20100216788-A1 | FUSED HETEROCYCLIC COMPOUND | GRK6, FGFR1, PTK6 | HSD17B1 1807/4885HSD17B2 1369/4885CYP3A4 692/4885 |
| US-11834430-B2 | Compounds useful as inhibitors of isoprenylcysteine carboxyl methyltransferase | ICMT, INMT, BHMT | HSD17B1 425/4885HSD17B2 559/4885CYP3A4 859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.